Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Oligonucleotides as inhibitors of human immunodeficiency virus.

Field AK.

Curr Opin Mol Ther. 1999 Jun;1(3):323-31. Review.

PMID:
11713797
2.

Non-specific antiviral activity of antisense molecules targeted to the E1 region of human papillomavirus.

Lewis EJ, Agrawal S, Bishop J, Chadwick J, Cristensen ND, Cuthill S, Dunford P, Field AK, Francis J, Gibson V, Greenham AK, Kelly F, Kilkushie R, Kreider JW, Mills JS, Mulqueen M, Roberts NA, Roberts P, Szymkowski DE.

Antiviral Res. 2000 Dec;48(3):187-96.

PMID:
11164505
3.

Human cytomegalovirus: challenges, opportunities and new drug development.

Field AK.

Antivir Chem Chemother. 1999 Sep;10(5):219-32. Review.

PMID:
10574177
4.

Viral targets for antisense oligonucleotides: a mini review.

Field AK.

Antiviral Res. 1998 Feb;37(2):67-81. Review. No abstract available.

PMID:
9588840
5.

Inhibition of the multiple antibiotic resistance (mar) operon in Escherichia coli by antisense DNA analogs.

White DG, Maneewannakul K, von Hofe E, Zillman M, Eisenberg W, Field AK, Levy SB.

Antimicrob Agents Chemother. 1997 Dec;41(12):2699-704.

6.

Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides.

Jairath S, Vargas PB, Hamlin HA, Field AK, Kilkuskie RE.

Antiviral Res. 1997 Feb;33(3):201-13.

PMID:
9037376
7.

Antisense inhibition of virus infections.

Kilkuskie RE, Field AK.

Adv Pharmacol. 1997;40:437-83. Review. No abstract available.

PMID:
9217933
8.

Antisense oligodeoxynucleotides against the BZLF1 transcript inhibit induction of productive Epstein-Barr virus replication.

Diabata M, Enzinger EM, Monroe JE, Kilkuskie RE, Field AK, Mulder C.

Antiviral Res. 1996 Mar;29(2-3):243-60. Erratum in: Antiviral Res 1996 Oct;32(2):117.

PMID:
8739603
10.

"The end of innocence" revisited: resistance of herpesviruses to antiviral drugs.

Field AK, Biron KK.

Clin Microbiol Rev. 1994 Jan;7(1):1-13. Review.

11.

Synthesis and antiviral activity of novel isonucleoside analogs.

Tino JA, Clark JM, Field AK, Jacobs GA, Lis KA, Michalik TL, McGeever-Rubin B, Slusarchyk WA, Spergel SH, Sundeen JE, et al.

J Med Chem. 1993 Apr 30;36(9):1221-9.

PMID:
8387600
12.

The structure and function of the HSV DNA replication proteins: defining novel antiviral targets.

Matthews JT, Terry BJ, Field AK.

Antiviral Res. 1993 Feb;20(2):89-114. Review.

PMID:
8384825
13.

Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds.

Slusarchyk WA, Bisacchi GS, Field AK, Hockstein DR, Jacobs GA, McGeever-Rubin B, Tino JA, Tuomari AV, Yamanaka GA, Young MG, et al.

J Med Chem. 1992 May 15;35(10):1799-806.

PMID:
1316966
14.

Oral bioavailability and anti-simian varicella virus efficacy of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) in monkeys.

Soike K, Huang JL, Tu JI, Stouffer B, Mitroka JG, Swerdel M, Olsen S, Bonner DP, Tuomari AV, Field AK.

J Infect Dis. 1992 Apr;165(4):732-6.

PMID:
1313071
15.

Selective activity and cellular pharmacology of (1R-1 alpha,2 beta,3 alpha)-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine in herpesvirus-infected cells.

Yamanaka G, Tuomari AV, Hagen M, McGeever-Rubin B, Terry B, Haffey M, Bisacchi GS, Field AK.

Mol Pharmacol. 1991 Sep;40(3):446-53.

PMID:
1896029
16.

Evaluation of SQ 34,514: pharmacokinetics and efficacy in experimental herpesvirus infections in mice.

Braitman A, Swerdel MR, Olsen SJ, Tuomari AV, Lynch JS, Blue B, Michalik T, Field AK, Bonner DP, Clark JM.

Antimicrob Agents Chemother. 1991 Jul;35(7):1464-8.

17.

Synthesis and antiviral activity of enantiomeric forms of cyclobutyl nucleoside analogues.

Bisacchi GS, Braitman A, Cianci CW, Clark JM, Field AK, Hagen ME, Hockstein DR, Malley MF, Mitt T, Slusarchyk WA, et al.

J Med Chem. 1991 Apr;34(4):1415-21.

PMID:
1849998
18.

(+-)-(1 alpha,2 beta,3 alpha)-9-[2,3-bis(hydroxymethyl)-cyclobutyl] guanine [(+-)-BHCG or SQ 33,054]: a potent and selective inhibitor of herpesviruses.

Field AK, Tuomari AV, McGeever-Rubin B, Terry BJ, Mazina KE, Haffey ML, Hagen ME, Clark JM, Braitman A, Slusarchyk WA, et al.

Antiviral Res. 1990 Jan;13(1):41-52.

PMID:
2159261
19.

Broad-spectrum antiviral activity of the acyclic guanosine phosphonate (R,S)-HPMPG.

Terry BJ, Mazina KE, Tuomari AV, Haffey ML, Hagen M, Feldman A, Slusarchyk WA, Young MG, Zahler R, Field AK.

Antiviral Res. 1988 Dec 1;10(4-5):235-51.

PMID:
2852486
20.

Synthesis and antiherpetic activity of (+/-)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine and related compounds.

Ashton WT, Meurer LC, Cantone CL, Field AK, Hannah J, Karkas JD, Liou R, Patel GF, Perry HC, Wagner AF, et al.

J Med Chem. 1988 Dec;31(12):2304-15.

PMID:
2848125
21.

Expression of herpes simplex virus type 1 DNA polymerase in Saccharomyces cerevisiae and detection of virus-specific enzyme activity in cell-free lysates.

Haffey ML, Stevens JT, Terry BJ, Dorsky DI, Crumpacker CS, Wietstock SM, Ruyechan WT, Field AK.

J Virol. 1988 Dec;62(12):4493-8.

22.

2'-Nor-2'-deoxyguanosine is an effective therapeutic agent for treatment of experimental herpes keratitis.

Davies ME, Bondi JV, Grabowski L, Schofield TL, Field AK.

Antiviral Res. 1987 Feb;7(2):119-25.

PMID:
3495237
23.

Efficacy of 2'-nor-cyclicGMP in treatment of experimental herpes virus infections.

Field AK, Davies ME, DeWitt CM, Perry HC, Schofield TL, Karkas JD, Germershausen J, Wagner AF, Cantone CL, MacCoss M, et al.

Antiviral Res. 1986 Oct;6(6):329-41.

PMID:
3022643
24.

Comparison of the modes of antiviral action of 2'-nor-deoxyguanosine and its cyclic phosphate, 2'-nor-cyclic GMP.

Germershausen J, Bostedor R, Liou R, Field AK, Wagner AF, MacCoss M, Tolman RL, Karkas JD.

Antimicrob Agents Chemother. 1986 Jun;29(6):1025-31.

25.

Enzymatic phosphorylation of the antiherpetic agent 9-[(2,3-dihydroxy-1-propoxy)methyl]guanine.

Karkas JD, Ashton WT, Canning LF, Liou R, Germershausen J, Bostedor R, Arison B, Field AK, Tolman RL.

J Med Chem. 1986 May;29(5):842-8.

PMID:
3009816
26.

Monoclonal antibody that inhibits infection of HeLa and rhabdomyosarcoma cells by selected enteroviruses through receptor blockade.

Crowell RL, Field AK, Schleif WA, Long WL, Colonno RJ, Mapoles JE, Emini EA.

J Virol. 1986 Feb;57(2):438-45.

27.

Phase I trials of poly(I,C) complexes in advanced cancer.

Krown SE, Kerr D, Stewart WE 2nd, Field AK, Oettgen HF.

J Biol Response Mod. 1985 Dec;4(6):640-9.

PMID:
2418162
28.

Synthesis and antiherpetic activity of (S)-, (R)-, and (+/-)-9-[(2,3-dihydroxy-1-propoxy)methyl]guanine, linear isomers of 2'-nor-2'-deoxyguanosine.

Ashton WT, Canning LF, Reynolds GF, Tolman RL, Karkas JD, Liou R, Davies ME, DeWitt CM, Perry HC, Field AK.

J Med Chem. 1985 Jul;28(7):926-33.

PMID:
2989523
29.

2'-Nor-cGMP: a seco-cyclic nucleotide with powerful anti-DNA-viral activity.

Tolman RL, Field AK, Karkas JD, Wagner AF, Germershausen J, Crumpacker C, Scolnick EM.

Biochem Biophys Res Commun. 1985 May 16;128(3):1329-35.

PMID:
2988534
30.
31.
32.

Effects of the nucleoside analog 2'-nor-2'-deoxyguanosine on human cytomegalovirus replication.

Tocci MJ, Livelli TJ, Perry HC, Crumpacker CS, Field AK.

Antimicrob Agents Chemother. 1984 Feb;25(2):247-52.

33.
34.
35.

9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication.

Field AK, Davies ME, DeWitt C, Perry HC, Liou R, Germershausen J, Karkas JD, Ashton WT, Johnston DB, Tolman RL.

Proc Natl Acad Sci U S A. 1983 Jul;80(13):4139-43.

36.
37.

Activation by thymidine kinase and potent antiherpetic activity of 2'-nor-2'-deoxyguanosine (2'NDG).

Ashton WT, Karkas JD, Field AK, Tolman RL.

Biochem Biophys Res Commun. 1982 Oct 29;108(4):1716-21. No abstract available.

PMID:
6295389
38.

Poly I:C/poly-L-lysine: potent inducer of interferons in primates.

Lampson GP, Field AK, Tytell AA, Hilleman MR.

J Interferon Res. 1981;1(4):539-49.

PMID:
7202031
39.

Replacement of animal serum proteins by human albumin for growth and interferon production by Namalva cells.

Field AK, Scattergood EM, Hopke CJ, Tytell AA, Hilleman MR.

Antimicrob Agents Chemother. 1980 Dec;18(6):930-2.

40.

Determination of antibodies of double-stranded RNA by enzyme-linked immunosorbent assay (ELISA).

Field AK, Davies ME, Tytell AA.

Proc Soc Exp Biol Med. 1980 Sep;164(4):524-9. No abstract available.

PMID:
6774344
41.
42.

Histomorphologic assessment of serum thymic factor treatment of NZB/NZW mice.

Mendlowski B, Field AK.

Clin Immunol Immunopathol. 1980 Feb;15(2):144-61. No abstract available.

PMID:
6965468
43.
44.

Failure of thymopoietin, ubiquitin and synthetic serum thymic factor to restore immunocompetence in T-cell deficient mice.

Martinez D, Field AK, Schwam H, Tytell AA, Hilleman MR.

Proc Soc Exp Biol Med. 1978 Nov;159(2):195-200. No abstract available.

PMID:
309608
45.

Safety assessment of poly I:C in NZB/NZW mice (38565).

Mendlowski B, Field AK, Tytell AA, Hilleman MR.

Proc Soc Exp Biol Med. 1975 Feb;148(2):476-83.

PMID:
1121498
46.

The effect of altering the size of poly C on the toxicity and antigenicity of poly I:C.

Lampson GP, Nemes MM, Field AK, Tytell AA, Hilleman MR.

Proc Soc Exp Biol Med. 1972 Dec;141(3):1068-72. No abstract available.

PMID:
4645754
47.

Demonstration of double-stranded ribonucleic acid in concentrates of RNA viruses.

Field AK, Lampson GP, Tytell AA, Hilleman MR.

Proc Soc Exp Biol Med. 1972 Nov;141(2):440-4. No abstract available.

PMID:
4673907
48.

Cellular control of interferon production and release after treatment with poly I:C inducer.

Field AK, Tytell AA, Lampson GP, Hilleman MR.

Proc Soc Exp Biol Med. 1972 Jun;140(2):710-4. No abstract available.

PMID:
4338804
49.

Poly I:C, an inducer of interferon and interference against virus infections.

Field AK, Tytell AA, Piperno E, Lampson GP, Nemes MM, Hilleman MR.

Medicine (Baltimore). 1972 May;51(3):169-74. No abstract available.

PMID:
4336643
50.

Antigenicity of double-stranded ribonucleic acids including poly I:C.

Field AK, Tytell AA, Lampson GP, Hilleman MR.

Proc Soc Exp Biol Med. 1972 Apr;139(4):1113-9. No abstract available.

PMID:
4623410

Supplemental Content

Loading ...
Support Center